The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of RPGR gene therapy for Retinitis Pigmentosa.
This technology includes an abbreviated version of the RPGR gene that is effective in gene replacement therapy for treating X-linked Retinitis Pigmentosa (XLRP). This condition is a genetic disorder that leads to progressive vision loss due to the degeneration of photoreceptor cells in the retina. The current version of RPGR is known to be unstable and can undergo changes in vivo, which may be harmful to recipient cells. The abbreviated RPGR retains its function, rescues the disease, and is stabilized, making it a safer option for gene therapy.
The technical solution involves using an adeno-associated viral vector that carries the abbreviated human RPGR cDNA. This vector supplies functional RPGR proteins to treat inherited ocular disorders related to RPGR mutations. This technology is significant because it addresses the instability issues of the current RPGR gene therapy approaches, providing a more reliable and effective treatment option for patients suffering from XLRP. Stakeholders in the ophthalmology and gene therapy fields should care about this innovation as it represents a potential breakthrough in treating a debilitating condition.
The licensing opportunity for this technology is open for collaboration with interested parties who are looking to develop and commercialize this gene therapy. The inventors are seeking partners who can assist in further development and potential market entry, ensuring that this promising therapy reaches those in need.